首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >The use of Tris-Lipidation to modify drug cytotoxicity in multidrug resistant cells expressing P-glycoprotein or MRP1
【2h】

The use of Tris-Lipidation to modify drug cytotoxicity in multidrug resistant cells expressing P-glycoprotein or MRP1

机译:Tris-Lipidation修饰表达P-糖蛋白或MRP1的多药耐药细胞的药物细胞毒性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="enumerated" style="list-style-type:decimal">Increasing the lipophilicity is a strategy often used to improve a compound's cellular uptake and retention but this may also convert it into a substrate for an ATP-dependent transporter such as P-glycoprotein or the multidrug resistance-associated protein (MRP1), which are involved in cellular efflux of drugs. Tris-Lipidation of compounds is a convenient way of modifying drug lipophilicity and generating an array of derivatives with diverse properties.To determine the effect of Tris-Lipidation on a drug's cytoxicity in multidrug resistant cells, various glycyl-Tris-mono- (GTP1), di- (GTP2) and tri-palmitate (GTP3) derivatives were prepared of the cancer chemotherapeutic drugs chlorambucil and methotrexate, and of the anti-HIV drug AZT. The cytotoxicity of these derivatives and their parent compounds was determined in the CEM/VLB100 cells with increased P-glycoprotein expression, the CEM/E1000 cells that overexpress MRP1 and the parent, drug-sensitive CCRF-CEM cells.Increasing the lipophilicity of AZT increased its cytotoxicity in the sensitive CCRF-CEM parental cell line while decreased cytotoxicity was observed for the methotrexate derivatives. For the chlorambucil derivatives, both increased (GTP1) and decreased (GTP2) cytotoxicity occurred in the CCRF-CEM cells. With the exception of AZT-GTP1, all GTP1 and GTP2 derivatives of chlorambucil, methotrexate and AZT had decreased cytotoxicity in the P-glycoprotein-expressing CEM/VLB100 cells while chlorambucil-GTP1, methotrexate-GTP2 and methotrexate-GTP3 were the only compounds with decreased cytotoxicity in the MRP1-overexpressing CEM/E1000 cells.The number of palmitate residues, the position of derivatisation and the type of linkage all may affect the P-glycoprotein and MRP1 substrate properties.Tris-Lipidation may therefore provide a useful way of manipulating the pharmacokinetic properties of drugs.
机译:class =“ enumerated” style =“ list-style-type:decimal”> <!-list-behavior =枚举前缀-word = mark-type = decimal max-label-size = 0-> 增加亲脂性是经常用于改善化合物的细胞摄取和保留的策略,但这也可能将其转变为涉及ATP的转运蛋白(例如P-糖蛋白或与多药耐药相关的蛋白(MRP1))的底物。在药物的细胞外排中。化合物的Tris-Lipidation是修饰药物亲脂性并生成一系列具有各种特性的衍生物的便捷方法。 要确定Tris-Lipidation对多药耐药细胞中药物细胞毒性的影响,可使用各种甘氨酰用癌症化疗药物苯丁酸氮芥和氨甲蝶呤以及抗HIV药物AZT制备了Tris-mono-(GTP1),di-(GTP2)和tri-palmitate(GTP3)衍生物。确定了这些衍生物及其母体化合物在P-糖蛋白表达增加的CEM / VLB100细胞,过表达MRP1的CEM / E1000细胞以及对药物敏感的母体CCRF-CEM细胞中的细胞毒性。
  • 增加AZT的亲脂性会增加其在敏感CCRF-CEM亲本细胞系中的细胞毒性,同时观察到甲氨蝶呤衍生物的细胞毒性降低。对于苯丁酸氮芥衍生物,CCRF-CEM细胞均发生了细胞毒性增加(GTP1)和降低(GTP2)的现象。除AZT-GTP1以外,苯丁酸氮芥,甲氨蝶呤和AZT的所有GTP1和GTP2衍生物在表达P-糖蛋白的CEM / VLB100细胞中均具有降低的细胞毒性,而苯丁酸氮芥-GTP1,甲氨蝶呤-GTP2和甲氨蝶呤-GTP3是仅有的降低了过表达MRP1的CEM / E1000细胞的细胞毒性。 棕榈酸酯残基的数量,衍生化的位置和键的类型都可能影响P-糖蛋白和MRP1底物的性质。因此, Tris-Lipidation可能为操纵药物的药代动力学特性提供有用的方法。
  • 著录项

    相似文献

    • 外文文献
    • 中文文献
    • 专利
    代理获取

    客服邮箱:kefu@zhangqiaokeyan.com

    京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
    • 客服微信

    • 服务号